At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 176 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 72
- Started
- 2023-07-10
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for transthyretin-related (attr) familial amyloid polyneuropathy
- • Clinical study - 72 participants
- • This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with transthyretin-related (attr) familial amyloid polyneuropathy
Where?
- • London - Clinical Trial Site
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyTransthyretin-Related (ATTR) Familial Amyloid CardiomyopathyWild-Type Transthyretin Cardiac Amyloidosis
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial...
- ✓A subject has provided agreement to take part for the LTFU study.
See the full criteria
Inclusion Criteria:
1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.
2. A subject has provided informed consent for the LTFU study.
Exclusion Criteria:
None
Where Is This Study? (1 UK site)
Clinical Trial Site
London, United Kingdom
Data sourced from ClinicalTrials.gov · Last verified: 2026-07
